Monitoring the efficacy and safety of Dihydro-Artémisinine-Piperaquine, Artemether-lumefantrine and Artesunate-Amodiaquine for malaria treatment
Not Applicable
- Conditions
- Malaria
- Registration Number
- PACTR201305000552290
- Lead Sponsor
- niversity Cheikh Anta DIOP of Dakar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
Subjects aged over 6 months with the uncomplicated P. falciparum malaria,
Parasite density between 1000 and 100000 trophozoites/¿l,
Presence of an axillary temperature higher than 37.5° or history of fever during the previous 24 hours,
Ability to take oral medication and given her inform consent were included in the study
Exclusion Criteria
Patients presenting mono-infestation by another species or mixted infestation, severe vomiting, severe malnutrition, severe signs of malaria (such as severe anemia, convulsion, respiratory distress), women with positive pregnancy test and patients who had a history of allergy to study drugs or not given her inform consent were excluded in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method adequate clinical and parasitological response (ACPR) after corrected PCR at day 28
- Secondary Outcome Measures
Name Time Method ACPR at days 35 and 42;Parasite and fever clearence time;Incidence of drug related adverse events